Lexeo Therapeutics, Inc.
LXEO
$8.66
$0.344.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -104.97M | -114.17M | -109.31M | -98.33M | -86.60M |
| Total Depreciation and Amortization | 2.06M | 2.04M | 2.03M | 2.00M | 1.97M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.62M | 10.70M | 13.83M | 12.45M | 10.03M |
| Change in Net Operating Assets | -13.52M | 6.37M | 5.45M | 2.73M | 7.79M |
| Cash from Operations | -106.81M | -95.07M | -88.00M | -81.15M | -66.81M |
| Capital Expenditure | -397.00K | -191.00K | -296.00K | -481.00K | -554.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.75M | -117.05M | -77.99M | -93.60M | -13.00K |
| Cash from Investing | -82.15M | -117.24M | -78.28M | -94.08M | -567.00K |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -480.00K | -508.00K | -460.00K | -410.00K | -399.00K |
| Issuance of Common Stock | 86.62M | 86.52M | 13.19M | 101.78M | 195.72M |
| Repurchase of Common Stock | -4.00K | -4.00K | -17.00K | -17.00K | -13.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13.21M | -13.21M | -12.58M | -12.58M | -6.36M |
| Cash from Financing | 72.93M | 72.80M | 133.00K | 88.78M | 188.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.03M | -139.51M | -166.15M | -86.45M | 121.57M |